Norwegian Registry of Lymphoid Malignancies
The Cancer Registry of Norway cooperates closely with clinicians, health trusts and pathology laboratories to create legitimacy and support in the national clinical communities in the work on the Norwegian Registry of. This cooperation is safeguarded by the establishment of a specialist council in the quality register with representatives from different regions and disciplines. The Cancer Registry of Norway is responsible for data processing.
The qualityegisteret shall contribute to strengthening the quality of health care for patients with lymphoid malignancies. The registry shall also conduct, promote and provide a basis for research to develop new knowledge about the causes, diagnosis and course of cancer, as well as treatment effects.
The treatment of lymphomas has become more differentiated, and results from studies are helping to adjust and change the guidelines for the treatment of lymphoid malignancies. New drugs and treatments are constantly being introduced that improve survival. Collecting data on all patients with lymphoid malignancies will provide a basis for assessing whether the guidelines are complied with and that patients receive the same health services regardless of where they live.
Information on the Norwegian Cancer Society's pages about lymphoma (lymphoma) and leukemia (includes lymphoid leukemias and multiple myeloma)
Registration to the register
Registration of clinical information to the Norwegian Registry of Lymphoid Malignancies is done electronically via KREMT on the Norwegian Health Network. KREMT has functions to make reporting easier.
Reminders for missing messages and receipts for submitted messages are available in the KREMT portal. It is also possible to cache forms.
To encourage reporting, administrative and clinical statistics have been compiled that provide hospitals with updated results for their unit. These statistics are updated daily.
The registry contains detailed information on all cases of lymphoma, lymphoid leukaemias and multiple myeloma (ICD10: C81 - C86 as well as C88, C90 and C91), as well as information from assessment and treatment of this patient group.
Following up this patient group in a quality registry can help reduce the burden of disease and treatment, and reduce late effects.
Patients with lymphoid malignancies are assessed, treated and followed up by both the primary health service and the specialist health service. All doctors who provide health care to patients with cancer are obliged to report to the Cancer Registry, which includes the Norwegian Registry of Lymphoid Malignancies.